Interview Study for Parents and Adolescents about Genetic Risk

Posted on April 5, 2018

If you are 15-17 years old or are the parent of a 15-17 year old, consider participating in an interview study with researchers at Johns Hopkins on communicating about genetic risk for Huntington’s disease. The 45-minute interview can be conducted by Skype or phone from anywhere in the USA, and each participant will be given…

Read more

HDSA’s Human Biology Project

Posted on March 29, 2018

The identification of the HD gene led to the development of many animal models that have helped us to better understand the biology of Huntington’s disease. However, in the hunt for effective therapies, the most relevant observations arise from studying human bodies, brains, and cells. In 2013, HDSA launched the Human Biology Project, to help…

Read more

25th Anniversary of Discovering the HD gene

Posted on March 22, 2018

This week marks 25 years since the identification of the gene that causes Huntington’s disease. The discovery of the repeating CAG sequence in the DNA was made in 1993 by the Huntington’s Disease Collaborative Research Group, an assembly of scientists across six institutions. They had united nearly a decade earlier, in 1984, after Jim Gusella’s…

Read more

New Partnership to Advance Treatments for Brain Disease

Posted on March 15, 2018

On Monday, HDSA announced a partnership with the ALS Association and Teva Pharmaceuticals on a project to help identify new drug targets for serious diseases of the nervous system, such as chronic pain, ALS, migraine, and Huntington’s disease. Teva is seeking proposals for new ways to design treatments for these and other neurological disorders through…

Read more

Interpreting this Week’s News: Data from the First Phase of the Ionis-Roche Trial

Posted on March 8, 2018

This week, Ionis Pharmaceuticals shared data from the successful safety trial for their huntingtin-lowering drug. The data confirms what was announced in December 2017: the drug safely lowers mutant huntingtin. No one taking the drug had a serious side effect, and no one dropped out of the trial – these are great signs of a…

Read more

CHDI’s Huntington’s Disease Conference in Palm Springs

Posted on March 1, 2018

This week in Palm Springs, California marks the 13th Annual HD Therapeutics Conference. This yearly conference draws academic and industry researchers from all over the world to share their work about Huntington’s disease and participate in discussions about the latest in HD drug discovery. HD Buzz is covering the 3-day conference in real time through…

Read more

Interpreting this Week’s News: Hope for Gene Therapy, and How to Get it to the Brain

Posted on February 22, 2018

Delivery of genetic therapies to the brain is one of the biggest challenges facing researchers in many fields of neurological disease, including HD. One novel approach, tested only experimentally in mice, is to use a type of harmless virus that can cross from the blood into the brain. Researchers at the University of North Carolina…

Read more

Interpreting This Week’s News: Fighting Cancer…With HD?

Posted on February 15, 2018

Research studies in recent years have shown that people with Huntington’s Disease and related hereditary CAG repeat disorders have lower rates of cancer than the general population. We’re not sure why that’s the case, but some scientists suspected that the HD gene and its toxic RNA message might actually have some cancer-fighting power. In a…

Read more

First HD-COPE Meeting

Posted on February 8, 2018

The first meeting of the Huntington’s Disease Coalition for Patient Engagement (HD-COPE) took place in London this week. HD-COPE unites organizations serving HD families in Europe, Canada, and the USA to help give patients a direct voice in clinical research by facilitating communication between the HD community and pharmaceutical companies working on drugs for HD….

Read more


Share Tweet

Share a link